ASCP 2023: A Phase 1 SAD and MAD Trial of EVX-101, a Novel Gastro-Retentive Prolonged Release
Presented at ASCP 2023, "A Phase 1 SAD and MAD Trial of EVX-101, a Novel Gastro-Retentive Prolonged Release". Find out about how Quotient Sciences can help accelerate your drug development program.
EuPFI: Taste Assessment Study of Tenapanor Pediatric Solution Formulations
Presented at EuPFI 2023, "Taste Assessment Study of Tenapanor Pediatric Solution Formulations".
On Demand Webinar: How to Accelerate Drug Product Optimization Using Translational Pharmaceutics®
Learn about our Translational Pharmaceutics approach to drug product optimization and hear insights from our scientific team. Watch our on-demand webinar today.
Strategies for Accelerating Pediatric Drug Development
In this whitepaper, Quotient Sciences highlights the key challenges that arise in pediatric formulation development, offers potential solutions, and discusses future trends and regulatory aspects that can help streamline pediatric medicines to patients faster.
Endevica Case Study - Peptide Program using Translational Pharmaceutics
Endevica Bio is developing TCMCB07 as a novel synthetic peptide product for the potential treatment of cachexia. Read how they leveraged the Quotient Sciences Translational Pharmaceutics platform for this program.
Ensysce Biosciences Case Study
Request a copy of our latest case study with Ensysce Biosciences about how our integrated strategies helped them achieve their regulatory milestones faster for PF614-MPAR, an Extended Release product.
Drug-Drug Interaction (DDI) Studies
Assessing how your drug interacts with other drugs in vivo is a critical step in the drug development process and is essential in ensuring safe and efficacious drug delivery. This assessment is known as a drug-drug interaction (DDI) study and is a regulatory requirement for submissions of investigational new drugs (INDs). Learn more about Quotient Sciences' offering for DDI studies.
CRS 2023 - Development of a Multi-Pill Abuse Resistant (MPAR®) Multiparticulate Modified Release Formulation to Prevent Opioid Overdose
Presented at CRS 2023, "Development of a Multi-Pill Abuse Resistant (MPAR®) Multiparticulate Modified Release Formulation to Prevent Opioid Overdose"
Reach the Clinic Faster: Integrated Biopharmaceutics & Drug Substance Strategies
Watch our on-demand, panel discussion webinar entitled 'Reach the Clinic Faster: Integrated Biopharmaceutics & Drug Substance Strategies'.
Peer Reviewed Publication
Astrazeneca - A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism and Excretion of Savolitinib in Healthy Male Volunteers
Quotient Sciences and Astrazeneca Co-Authored Scientific Publication evaluating Savolitinib in healthy male volunteers.
Strategies for Achieving Regulatory Milestones Faster
Watch our on-demand webinar featuring a customer case study from Ensysce Biosciences' CEO Lynn Kirkpatrick on choosing an integrated service provider to accelerate drug development.